Core Insights - Bionano Genomics is showcasing advancements in Optical Genome Mapping (OGM) for hematologic malignancies at the Bionano Symposium 2026, emphasizing its role in enhancing genomic analysis and precision medicine [1][11] Group 1: Event Overview - The Bionano Symposium 2026 has over 1000 registered attendees from 70 countries, making it the largest event dedicated to OGM and Bionano solutions in 2026 [1] - The symposium features global experts discussing how OGM is transforming cytogenetic and molecular workflows in the study of leukemias, lymphomas, and multiple myeloma [1][11] Group 2: Presentations and Findings - Dr. Alka Chaubey presented on the functionality of OGM, highlighting its enhanced resolution and sensitivity compared to traditional methods like karyotyping, FISH, and NGS [2][3] - Dr. Ravindra Kolhe compared OGM with traditional cytogenetic methods, emphasizing the integration of OGM and NGS for comprehensive cancer genomics analysis [4] - Dr. Wahab A. Khan demonstrated OGM's ability to uncover complex structural variants in chronic lymphocytic leukemia that standard methods fail to detect [5] - Amber Verhasselt showcased OGM's effectiveness in identifying pathogenic aberrations in non-Hodgkin lymphoma across various specimen types [6] - Dr. Elly De Vlieghere illustrated how OGM can replace multiple traditional assays in multiple myeloma, providing more comprehensive answers [7] - Dr. Rashmi Kanagal Shamanna presented expert recommendations from the International Consortium of OGM regarding its use in various hematologic malignancy subtypes [8] Group 3: Future Implications - The session concluded with a panel discussion on best practices for implementing OGM in routine research, indicating its growing importance in hematologic malignancy studies [10] - Bionano's leadership expressed optimism about OGM's potential to transform genomic analysis and improve understanding of complex genomic events [11]